Batch of H1N1 Vaccine Pulled Due to Severe Allergic Reactions
December 10, 2009
Health officials across Canada are being asked to hold back a batch of swine flu vaccine that appears to be causing higher rates of severe allergic reactions.
The vaccine's manufacturer, GlaxoSmithKline, is asking governments to stop using vaccine doses from one particular lot shipment issued in late October.
Bloomberg reports that Glaxo advised Canadian doctors to hold off on using a batch of the vaccine while the company probes reports of higher-than-expected occurrences of a side effect known as anaphylaxis.
The batch of 172,000 doses of Arepanrix was linked to more cases of acute allergic reactions, including swollen tongues, throats and respiratory distress, than expected, spokeswoman Gwenan White said.
According to Manitoba health officials, severe allergic reactions from the batch in question were seen in one of 20,000, which is far higher than the typical rate of one in 100,000.